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Abstract 
Objectives Fatigue is an important determinant of altered quality of life in patients affected by 
chronic hepatitis C (CHC) or the irritable bowel syndrome (IBS). In this study, we aimed at 
determining the contributory role of plasma levels of leptin and carnitine on fatigue in CHC 
and IBS. Methods We enrolled 70 patients with CHC, 42 with IBS and 44 healthy subjects. 
Fatigue was evaluated using the Fatigue Impact Scale questionnaire. Body composition was 
assessed through impedance analysis. Plasma carnitine and leptin were measured. Results 
Fatigue scores were significantly more elevated in patients with CHC and IBS than in healthy 
subjects. Patients with CHC, but not with IBS, had significant lower plasma levels of total and 
free carnitine adjusted for fat mass compared to healthy subjects. In patients with CHC, and 
not with IBS, fatigue scores were negatively correlated with plasma levels of carnitine. Levels 
of free carnitine were significantly and independently associated with the severity of fatigue 
in patients with CHC (OR=2.019, p=0.02, CI 95% [1.01-1.23]).Conclusions In patients with 
CHC, the severity of fatigue is associated with low level of carnitine, suggesting that an oral 
supplementation may be effective to relieve fatigue in CHC. The underlying mechanism of 
fatigue in IBS does not seem to involve carnitine. 
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Introduction 
 
Fatigue is one of the most common complain reported by patients in primary care settings 1. 
This persistent feeling of exhaustion and decrease capacity for physical and mental work is a 
ground state for many diseases and common symptom of various chronic digestive illness 
such as chronic hepatitis C (CHC) 2, primary biliary cirrhosis 3 1, and also functional bowel 
disorders, namely the irritable bowel syndrome (IBS) 4. To date, no proper fatigue-related 
biochemical changes have been established, therefore identifying alterations of biochemical 
parameters would be helpful to understand the complexity of fatigue in the hope for future 
therapies.  
 
As described by Swain and Maric 5 6, three major central changes have been implicated; (i) 
neuroendocrine causes, with abnormal function of the hypothalamic-pituitary-adrenal (HPA) 
axis; (ii) abnormalities in neurotransmission, particularly in the central serotonin pathway and 
(iii) alteration in immune activation and cytokines release, in particular the adipokine leptin. 
For example, in patients with chronic liver diseases, we have shown that the severity of 
fatigue was associated with high leptin levels in both primary biliary cirrhosis and CHC, in 
the latter, with a concomitant increase of the tumor necrosis factor α (TNF-α) levels, one 
major secretagogue of leptin 2. We have also subsequently found a close association between 
the severity of fatigue and plasma leptin levels adjusted for fat-mass in a cohort of patients 
with IBS, suggesting a non-specific contribution of leptin in the complexity of fatigue 
associated with digestive and liver diseases 4. 
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L-carnitine is an endogenous compound absorbed in the intestine by a combination of active 
transport and passive diffusion 7. The heart, skeletal muscle, liver, kidneys and epididymis 
have specific transport system for carnitine that concentrate carnitine within these tissues. 
Carnitine's primary mechanism of action is apparently attributable to its role as a cofactor in 
the transformation of free long-chain fatty acids into acyl carnitine for subsequent transport 
into the mitochondrial matrix 8. The well-established roles in energy production and 
modulation of the mitochondrial coenzyme A (CoA)/acyl-Coa ratio in the skeletal muscle, 
suggests that carnitine supplementation might increase fatty acid oxidation, thus making more 
ATP available for mechanical work and delaying fatigue development 9. In human, a serum 
acylcarnitine deficiency has been observed in certain types of diseases such as patients with 
chronic fatigue syndrome 10 and CHC 11. However, plasma carnitine levels have never been 
evaluated in patients having IBS and fatigue. Interestingly, administration of carnitine to 
healthy elderly subjects has been shown to exert a favorable effect on fatigue and serum lipids 
12
. Moreover, carnitine supplementation is relevant for the fatigue treatment of cancer 
chemotherapy 13, multiple sclerosis 14, fibromyalgia 15 haemodialysis 16, celiac disease 17 and 
also in patients with CHC who received interferon therapy 18. Interestingly, experimental 
findings support that carnitine palmitotransferase-1 linked fatty acid oxidation is a key 
modulator of leptin expression 19. In healthy ponies, carnitine supplementation has been 
associated with enhanced glucose tolerance and increase in leptin concentration 20. 
In this study, we aimed at determining the contributory role of plasma levels of carnitine on 
fatigue in patients with untreated CHC and IBS. 
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Patients and Methods 
 
Participants 
 
Forty two patients with IBS (34F, 8M, mean-age 50.7±13.6 yrs) were included prospectively 
in the study during a 6-month recruitment period. The presence of IBS was determined 
according to the Rome II criteria following exclusion of organic disease. These criteria 
required the presence of abdominal pain or discomfort relieved by defecation or associated 
with change in stool form or frequency, together with at least two of the following symptoms: 
altered stool frequency (> 3 per day or < 3 per week), altered stool passage 
(straining/urgency), passage of mucus, bloating and/or abdominal distension. These 
symptoms had to be present more than 25% of the time. Patients were diagnosed with 
predominant constipation (IBS-C) if they reported abdominal pain or discomfort associated 
with a primary alteration in bowel function consistent with constipation (i.e. infrequent hard 
stools or increased straining to pass stools). Patients were categorized with predominant 
diarrhea (IBS-D) if they reported abdominal pain or discomfort associated with primary 
alterations in bowel function consistent with diarrhea (i.e. frequent loose or watery stools and 
urgency). Patients with alternating symptoms (IBS-A) of constipation and diarrhea were also 
included with at least one of the criteria required for the diagnosis of IBS-C or IBS-D.  
The following exams were performed: laboratory blood tests (including erythrocyte 
sedimentation rate, C reactive protein, hemoglobin level, leukocyte count, electrolytes, liver 
function tests, pancreatic amylase, Human imunodeficiency and hepatitis C and B viruses, 
and thyroid function tests); a gastroscopy with biopsy specimen of the duodenum; an 
abdominal ultrasound or a computed tomography; and finally a fecal culture (also looking for 
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ova and parasites). A colonoscopy was performed in all patients and biopsy specimens were 
taken if diarrhea was predominant. 
 
Eighty one patients admitted to our liver unit for compensated liver disease due to CHC (47F, 
34M, mean age 43.7±12.3 years) were included in the study. The diagnosis of CHC was based 
on the association of: (a) elevation of serum alanine aminotransferase (ALT) above 40 U/l 
(upper normal limit) for six months or longer, (b) presence of anti-hepatitis C virus (HCV) 
antibodies, (c) presence of HCV viraemia, and (d) exclusion of other causes of chronic liver 
disease (alcoholism, chronic hepatitis B, Wilson’s disease, hepatotoxic drugs, 
haemochromatosis, α1 antitrypsin deficiency, autoimmune chronic active hepatitis). A liver 
biopsy was performed in all patients, none of whom was cirrhotic. These patients had no 
evidence of dehydration or overhydration or any other acute or chronic disease suspected of 
causing hypermetabolism (including human immunodeficiency virus). Furthermore, none had 
renal failure, thyroid disease, or clinically apparent depression, and none was treated with beta 
blockers or had received antiviral therapy. 
 
Forty-four healthy volunteers (34F, 8M, mean age 46.5±17.3 yrs) were recruited by 
advertisement during the same period and formed the control group. These subjects were 
considered normal on the basis of history, physical exam and biochemical blood screening 
and were enrolled if they did not have any digestive symptom. None of them experienced 
fatigue and depression that were excluded by a psychiatrist. All clinical studies were 
performed according to the declaration of Helsinki, and all participants gave their written 
informed consent. 
 
Questionnaires 
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Participants were systematically asked for fatigue and were convened to complete a self-
reported measure pertaining to the psychological state (e.g. fatigue). Fatigue was measured 
using the French version of the Fatigue Impact Scale (FIS) questionnaire which was used by 
us in patients with chronic hepatitis C 2 and IBS 21. FIS is a self-report questionnaire 
consisting of 40 statements that describes possible manifestations of fatigue; these statements 
are divided in three categories (cognitive [n=10], physical [n=10], psychosocial [n=20] ). 
Each item is rated on a five-point scale of distress, ranging from 0 (“no problem") to 4 
("extreme problem") with a maximum of 160 points. In addition to the 40 items, the FIS asks 
for the frequency of fatigue in terms of days per month and the usual duration of fatigue per 
day. The FIS also includes a visual analog scale (VAS) allowing evaluation of the "disabling 
effect" of fatigue on a scale of 1 ("no disabling effect") to 10 ("severe disabling effect"). 
 
Bioelectrical impedance analysis 
 
Body composition was measured in the morning, after a 12-hours overnight fast (including 
alcohol and drugs and no smoking) in the Functional Explorations Unit of the department of 
Gastroenterology. Body composition was measured by bipolar bioelectrical impedance 
analysis (BIA) with an alternating electric current (50 µA) at two frequencies: 1 MHz and 5 
kHz, as previously described and validated by Boulier et al 22. Measurements were taken in 
the conditions described hereafter. The subjects were supine for 30 min, arms relaxed along 
their side but not touching the body. Body mass index (BMI) is expressed as weight per 
height squared (kg/m2). 
 
Plasma biochemical analysis 
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All plasma samples were collected at 08:00 AM in both IBS and controls and were stored in 
duplicate at -80°C until assayed. Plasma cortisol, ACTH and TSH levels were used to 
evaluate basal HPA axis as well as thyroid functions. Serum leptin levels were measured 
using a specific radioimmunoassay for human leptin (Linco Research, St. Charles, MO, USA) 
with a limit of detection of 0.5 ng/mL. The intra- and inter-assay coefficients of variation 
were less than 8%. Acylcarnitines samples were prepared for analysis as following: 10µL of 
plasma sample is extracted with 100 µl of methanolic solution containing stable isotope-
labeled acylcarnitines internal standards (Cambridge Isotope Laboratories, Inc. #NSK-B) for 
20 min at ambient temperature.  
The methanolic eluates were dried under nitrogen, and reconstituted with 100 µl of mobile 
phase (water/acetonitrile v/v, 0.02% formic acid) prior to analysis.  
Electrospray MS/MS was performed on an API3000 model tandem mass spectrometer 
(Applied Bioystems, Foster City, CA). Acylcarnitine standards including free, acetyl, 
propionyl, butyryl, hexanoyl, octanoyl, decanoyl, dodecanoyl, tetradecanoyl, palmitoyl and 
stearoyl carnitines were purchased from Dr. HJ ten Brink (VU Medical Center, Amsterdam, 
The Netherlands) and allowed to establish standard curves for quantitation. 
 
Statistical analysis 
 
Quantitative data were expressed as mean ± SD and were compared using the Mann-Whitney 
U-test. The Chi-2 test was used to compare qualitative data. The independent predictors of 
fatigue were determined using a multiple logistic regression model. A p value < 0.05 was 
considered significant. 
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Results 
 
Characteristics of the study population 
 
The characteristics of the study populations are presented in Table 1. The percentage of 
female was significantly (p=0.0002) more elevated in patients with IBS (80.9%) than in 
patients with CHC (42%) or controls (52,2%). Patients with CHC were significantly younger 
than IBS patients (43.7±12.3 vs 50.7±13.6, years p=0.03). Patients with IBS had significantly 
higher BMI than patients with CHC or controls (27±5 vs 24±4 and 23±4 kg/m2, p=0.008 vs 
CHC and p=0.007 vs controls, respectively).  
 
Evaluation of fatigue 
 
Overall, 46% of patients with CHC and 55% of patients with IBS verbally expressed fatigue 
and rated more than 4 on the visual analog scale. Among IBS patients, 20% considered that 
fatigue was the worst symptom of their disease whereas 45% observed that it was as disabling 
as their digestive symptoms. The total score of fatigue was significantly higher in IBS 
patients (68.4±32.9) and CHC patients (56.0±39.8) than in controls (15.5±11.6, p<0.0001 vs 
IBS and CHC). Fatigue scores were not different between IBS subtypes. Table 2 presents 
fatigue scores according to the sex of both patients and controls. There were no significant 
differences between patients with CHC or IBS among each subscale of fatigue (Figure 1). 
 
Carnitine and leptin assessments 
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Due to the sex dependency of body composition, leptin and carnitine biological findings are 
presented in Table 3 in both male and female patients and controls. 
 
Absolute plasma leptin levels were significantly higher in IBS patients (32.8±26.2 ng/ml) 
than in patients with CHC (15.0±19.4 ng/ml, p<0.0001 vs IBS) and controls (7.4±5.2 ng/ml, 
p<0.0001 vs CHC). When adjusted for fat mass or BMI, leptin levels were significantly 
higher in IBS (1.8±2.8 ng/mL.Kg-1 and 11.6±9.4 ng/mL.Kg/m2respectively) than in CHC 
(0.6±0.6 ng/mL.Kg-1  and 5.9±7.0 ng/mL.Kg/m2 p<0.0001 and p=0.0002 respectively) or in 
CHC than in controls (0.5±0.4 ng/mL.Kg-1 and 3.0±2.1 ng/mL.Kg/m2, p=NS and p=0.03 vs 
CHC respectively).  
 
Absolute plasma levels of total carnitine were similar among patients with CHC (44.7±10.1 
ng/mL), IBS (47.0+10.1ng/mL) and controls (47.1±10.1 ng/mL, p=NS). Similarly, absolute 
plasma levels of free carnitine were not significantly different among patients with CHC 
(36.0±8.5 ng/mL), IBS (36.7±8.9 ng/mL) and controls (36.7±8.9 ng/mL). When adjusted for 
fat mass, total and free carnitine levels were significantly lower in CHC (2.7±1.6 and 2.2±1.3 
ng/mL.Kg-1) than in controls (4.5±4.3 and 3.5±3.6 ng/mL.Kg-1, p=0.02 and p=0.02 
respectively). In IBS patients, there were a statistical trend favor to lower total and free 
carnitine levels compared to controls (2.9±4.7 and 2.4±4.6 ng/mL.Kg-1, p=0.08 and p=0.12 
respectively) (Figure 2).  
 
Correlation analysis 
 
In patients with CHC, the total score of fatigue was significantly correlated with leptin 
(r=0.30, p=0.009), leptin adjusted for fat mass (r=0.31, p=0.01). The total score of fatigue 
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also correlated with total (r=-0.41, p=0.0003) and free (r=-0.43, p=0.0001) carnitine levels 
even when adjusted for fat mass (r=-0.23 p=0.03 and r=-0.22, p=0.04) (Figure 3). There were 
no significant relationship between plasma levels of carnitine and the degree of fibrosis 
and/or inflammation observed in liver biopsy specimens. 
In patients with IBS, the total score of fatigue was significantly correlated with leptin (r=0.31, 
p=0.04), leptin adjusted for fat mass (r=0.25, p=0.03), but not with total or free carnitine 
levels even when adjusted for fat mass.  
 
In CHC patients, the following parameters were included in a multiple logistic regression 
model: METAVIR score activity and fibrosis, leptin, BMI, fat mass, age, sex, and free 
carnitine levels. Only free carnitine levels were significantly and independently associated 
with the severity of fatigue (OR=2.019, p=0.02, CI 95% [1.01-1.23]). 
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Discussion 
 
In the present study, we showed that fatigue, evaluated with the Fatigue Impact Scale 
questionnaire, altered equally patient's quality of life in both CHC and IBS. We found that 
plasma leptin was associated with the severity of fatigue in both CHC and IBS. Moreover, our 
findings revealed a carnitine deficiency in patients with CHC, but not with IBS, and that 
carnitine levels were negatively correlated with fatigue scores in CHC only. Whether 
carnitine is specifically related to fatigue in CHC remains to be further elucidated.   
 
Because chronic fatigue is comm nly reported in more than 20% of people 23, it is necessary 
to study what cause fatigue and to develop treatments for it. To date, no specific fatigue 
related changes have been clearly established, leading to major limitations to determine the 
influence of fatigue on the disease process. Thus, identifying alterations of biochemical 
parameters would enable to understand the underlying mechanisms of fatigue. In the present 
study, the Fatigue Impact Scale questionnaire allowed an evaluation of the perceived impact 
of fatigue on patients' - lives, the factors that affect patients' perceptions of fatigue, and the 
affect of fatigue on the mental and general health of patients. As previously reported, we 
found that the severity of fatigue was markedly increased in both CHC and IBS patients, 
particularly in females, involving all three domains exploring quality of life (i.e. cognitive, 
physical, and psychosocial) 4 2 24. We also retrieved significant positive correlations between 
plasma leptin levels adjusted for fat mass and the total score of fatigue in both patients with 
CHC and IBS further arguing for the role of the adipokine leptin in the sequence leading to 
fatigue.  
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In the current study, patients with CHC, but not with IBS, had significant lower levels of total 
and free carnitine adjusted for fat mass as compared to healthy subjects. These findings are in 
accordance with those of Kuratsune et al. 11 who found low levels of serum acylcarnitine (e.g. 
carnitine deficiency) in chronic fatigue syndrome and CHC, but not in other diseases. In our 
study, all patients were evaluated in same conditions, completing questionnaires in the 
morning and having no major changes of their daily activities (e.g. physical & psychosocial) 
and/or dietary habits in the past 4 weeks. Although the mechanism involved in the occurrence 
of carnitine deficiency in CHC has not been investigated in the present study, it could be 
cautiously speculated that virus C infection may alter the physiological process of carnitine 
biosynthesis in the liver.  
 
In our study, we found significant negative correlations between circulating carnitine levels 
(e.g.total and free) and fatigue scores in patients with CHC but not in IBS. Moreover, in a 
logistic model of regression, free carnitine was significantly associated with fatigue, 
independently from age, sex, fat mass, METAVIR score (both activity and fibrosis), BMI and 
leptin. In patients with CHC, similar strength of associations between carnitine levels and 
each domain of fatigue were observed (data not showed), thus arguing for a non-specific 
contributory role of carnitine in the development of both mental and physical fatigue. 
Although our study cannot address further the mechanism underlying fatigue in CHC, it is 
tempting to speculate on the relationship between carnitine and liver inflammation. Indeed, 
Selimoglu et al. 25 found that plasma carnitine levels were lower in children with chronic 
hepatitis B compared with healthy ones and that carnitine was inversely correlated with liver 
portal inflammation and fibrosis scores. In the present work, although significant lower levels 
of carnitine adjusted for fat mass were observed in CHC patients, we found no relationship 
between carnitine and the degree of liver fibrosis and/or inflammation. In fact, we believe that 
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this should be interpreted with caution since blood samples were not concomitant to liver 
biopsy (e.g. up to 8 months), liver contents of carnitine were not assessed and only 13% of 
CHC patients had a METAVIR score activity up to 2. 
 
Our study has also other limitations. In the present work, we did not evaluate numerous other 
biological candidates that could play a role in the development of fatigue in human 26. 
Moreover, a more marked effect of carnitine on physical fatigue was not explored since all 
patients and controls were not evaluated while on physical tasks 26. We did not perform 
specific dynamic challenges of the HPA axis and repeated circulating levels of both leptin and 
carnitine which would have been helpful to identify more subtle biological disturbances 27. 
Moreover, we did not analyze liver biopsy specimens, which would have also been relevant to 
consider the relationship between immune activation, plasma cytokines and carnitine. Finally, 
increasing the sample size of patients would have probably unmask significant higher levels 
of carnitine in male patients in particular in the IBS group. 
 
The present findings have important and practical clinical consequences in the hope to reduce 
fatigue and increase adherence to antiviral therapy in CHC. Indeed, there are few available 
effective therapies for fatigue associated with CHC. We have previously documented that the 
5-hydroxytryptamine receptor type 3 antagonist ondansetron had a significant positive effect 
on fatigue in CHC. However, its use may be impinged by a relative high rate of constipation 
that occurred in patients who received active drug 28. Given the fact that emerging evidence 
from an uncontrolled study 18 has suggested that CHC patients treated with interferon in 
association with carnitine (2g daily) showed a marked and early significant reduction of 
fatigue levels, our findings provide good reasons to pursue larger trials on the possible benefit 
of carnitine supplementation in CHC patients reporting fatigue.  
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In conclusion, we have shown that fatigue alters equally patient's quality of life in both CHC 
and IBS. Our findings suggest that carnitine may play a contributory role in the occurrence of 
fatigue associated with CHC but not in IBS. Whether the relationship between fatigue and 
carnitine involves a specific pathway in CHC requires further investigations. Finally, the 
benefit of carnitine supplementation may be evaluated in future randomized trials aimed at 
reducing fatigue and increasing adherence to available antiviral therapies. 
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Figure legends: 
 
Figure 1: Analysis of the total score and each domain of fatigue patients with chronic 
hepatitis C (CHC), irritable bowel syndrome (IBS) and controls. a p<0.001 vs CHC and IBS 
 
Figure 2: Comparisons of circulating levels of free and total carnitine adjusted for fat mass 
between patients with chronic hepatitis C or irritable bowel syndrome and healthy subjects. 
 
Figure 3: Correlation between the total score of fatigue and absolute plasma levels of total 
and free carnitine (left of the panel) and total and free carnitine adjusted for fat mass (right of 
the panel) in patients with chronic hepatitis C. 
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Table 1: Characteristics of patients with hepatitis C, irritable bowel syndrome and controls. 
 Hepatitis C IBS Controls P value 
Sex (F/M) 34/47 34/8 23/21 <0.001 
Age (years) 43.7±12.3a 50.7±13.6 46.5±17.3 a 0.03 vs IBS 
BMI (Kg/m2) 24±4 27±5a 23±4 a 0.008 vs 
hepatitis C and 
0.007 vs controls 
Fat mass (Kg) 20.3±9.6 a 25.2±11.6 b 16.3±9.2 a
 0.04 vs controls 
and 0.02 vs IBS 
b
 0.0002 vs 
controls 
Fat-free mass 
(Kg) 
49.4±11.3 46.9±9.1 50.8±9.4 NS 
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Table 2: Fatigue scores in patients with chronic hepatitis C, irritable bowel syndrome and 
controls according to the sex. 
 CHC  IBS  Controls  
 F M p F M p F M p 
Total score 77.1±38.4 42.6±36.2 0.001 71.1±34.1 56.0±26.3 0.2 15.9±10.7 15.9±12.6 0.8 
psychosocial 36.7±19.3 19.5±19.0 0.001 35.2±18.6 23.0±17.3 0.2 7.4±7.5 6.1±5.4 0.3 
physical 21.8±9.6 12.8±9.7 0.002 19.3±9.5 17.4±7.7 0.5 4.5±3.5 4.9±4.7 0.8 
cognitive 18.6±11.5 10.3±8.8 0.002 18.4±9.4 12.4±8.3 0.1 3.9±3.9 4.8±4.4 0.5 
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Table 3: Plasma levels of leptin and carnitine in patients with chronic hepatitis C, irritable 
bowel syndrome and controls according to the sex. 
 CHC  IBS  Controls  
 F M p F M p F M p 
Leptin 
(ng/mL) 
24.6±23.9 7.8±10.9 0.0002 38.0±26.2 9.2±3.5 0.02 9.4±4.3 5.4±5.4 0.02 
Leptin/BMI 
(ng/mL 
Kg/m2) 
9.0±6.7 2.9+3.7c 0.0001 13.8±9.6 3.4±1.5 0.02 4.1±2.0 2.0±1.7 0.005 
Leptin/FM 
(ng/mL.Kg-1) 
1.0±0.6 0.3±0.4 0.0001 2.1±3.0 0.4±0.1 0.2 0.6±0.5 0.4±0.3 0.04 
Total 
carnitine 
(ng/mL) 
42.7±12.3 46.2±8.0 0.1 46.4±10.3 49.7±9.6 0.09 43.1±5.8 49.1±12.3 0.07 
Free 
carnitine 
(ng/mL) 
33.8±9.9 37.7±6.9 0.06 37.2±7.7 41.7±6.3 0.2 33.6±5.5 39.8±10.5  0.04 
Total 
carnitine/ FM 
(ng/mL.Kg-1) 
2.3±1.4 3.0±2.3 0.05 2.9±1.2 2.9±5.2 0.9 2.7±1.3 6.0±5.6 0.01 
Free 
carnitine/FM 
(ng/mL.Kg-1) 
1.8±1.1 2.4±1.3 0.05 2.4±4.5 2.5±1.1 0.8 2.1±1.1 4.9±4.7 0.01 
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